US-listed diabetes specialist Generex Biotechnology Corp has entered into a product licensing and distribution agreement with ABP-Comercio, Importacao E Exportacao, for the registration, importation, marketing, distribution and sale in Brazil of Glucose RapidSpray, its proprietary glucose buccal spray product.
According to the firm, the product is an alternative for people who want additional glucose in their diet. Glucose RapidSpray delivers a fat-free, low-calorie glucose formulation developed using the company's proprietary buccal drug delivery technologies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze